Lyeons Raises £129K Seed for Non-Invasive Nervous System Regulation Devices

Lyeons Raises £129K Seed Round

Lyeons, a Cambridge-based neurotechnology startup, has raised £129,000 in seed funding. The round was announced on September 11, 2026.

What Lyeons Does

Lyeons builds non-invasive, body-first devices for nervous system regulation and everyday brain health. The company was founded in 2024 and is based in Cambridge, United Kingdom.

Its first product, the LYEONS Heart, is a portable device that uses gentle, heartbeat-like audio-tactile sensory stimulation. According to the company, the device is designed to help people manage:

• Stress
• Anxiety
• Sleep difficulties
• Sensory overload

The approach is described as body-first, meaning the device works through sensory input rather than through invasive or implanted technology.

Company Background

Lyeons is led by founder Lucy Jung. The company is currently running beta user cohorts while building clinical evidence alongside researchers, clinicians, and partners in the Cambridge ecosystem.

That combination — early user testing plus a research-oriented evidence strategy — places Lyeons in the pre-commercial phase typical of seed-stage neurotechnology and consumer health hardware companies.

The Round

• Round type: Seed
• Amount raised: £129,000 GBP
• Announcement date: September 11, 2026
• Lead investor: Not disclosed
• Participating investors: Not disclosed

The round is small by seed standards, consistent with an early-stage company that is still validating its first product through beta cohorts and clinical evidence work.

Why It Matters

Nervous system regulation has become an active area at the intersection of consumer wellness hardware and clinical research. Devices in this space typically aim to influence stress response, sleep, or sensory processing through non-invasive means.

Lyeons' specific approach — heartbeat-like audio-tactile stimulation delivered through a portable device — targets everyday use cases rather than clinical-only settings. The company's stated focus on building clinical evidence alongside researchers and clinicians suggests it intends to support its consumer positioning with research validation.

Acquisition Angle

At seed stage with a £129,000 round, Lyeons is an early-stage asset. For acquirers and investors tracking neurotechnology and consumer health hardware, several characteristics are notable:

• Category: Non-invasive nervous system regulation and brain health devices, a segment that bridges consumer wellness and clinical research.
• Product focus: A single flagship device, the LYEONS Heart, with defined use cases in stress, anxiety, sleep, and sensory overload.
• Evidence strategy: Active work with researchers, clinicians, and Cambridge ecosystem partners to build clinical evidence.
• Geography: Cambridge, UK, a recognized hub for neurotechnology and life sciences research.
• Founder-led: The company is led by founder Lucy Jung.

What to Watch

The key milestones for Lyeons will be the results of its beta user cohorts and the progress of its clinical evidence work. For a seed-stage hardware company, those two tracks — user validation and research validation — typically determine whether the product moves toward broader commercial availability.

For acquisition-oriented readers, Lyeons represents an early-stage entry in the non-invasive neurotechnology space, with a defined first product and an explicit evidence-building strategy anchored in the Cambridge research ecosystem.